Introduction
B cell chronic lymphocytic leukemia (B-CLL) is the most common adult leukemia in the western hemisphere, accounting for a quarter of all leukemias (reviewed in Ref. 1) . While patients with early stage, indolent disease survive a median 11 years, patients with advanced stage B-CLL have a median survival of 1.5-3 years with few therapeutic options that impact overall survival. Furthermore, all B-CLL patients have impaired immune function; thus the natural course is characterized by increased infections, secondary malignancies, and autoimmune complications. Therefore, new therapeutic strategies are needed for patients with B-CLL.
Current treatment for B-CLL depends on disease stage. Indolent disease may not benefit from any treatment. 1 Fludarabine (9-␤-d-arabinofuranosyl-2-fluoroadenine-5Ј-monophosphate; F-ara-AMP) is now considered by some as an acceptable first-line therapy for B-CLL, since a direct comparison with chlorambucil demonstrated significant advantages in both response rates and disease-free survival. 2 However, despite a response rate of 50-70% in previously untreated patients, all patients eventually relapse with fludarabinerefractory disease, and to date there is no standard salvage therapy. Regimens combining alkylators with the topoisomerase II inhibitor, doxorubicin, 3, 4 and anti-CD52 monoclonal antibodies 5 have been used to treat advanced or recurrent disease.
B-CLL cells generally manifest decreased apoptosis and resistance to apoptosis. [6] [7] [8] This is likely mediated in part by increased expression of bcl-2 6 and by chronic activation of endogenous inducible NO synthase (NOS2) and intracellular NO, [7] [8] [9] a molecule that can inhibit apoptosis by nitrosylating caspases. [10] [11] [12] In contrast to low-level, endogenous NO, exogenous NO can induce apoptosis of normal and malignant cells, including leukemia cells. 13 The purpose of this study was to determine the effect of combining chemotherapeutic agents that target DNA metabolism with NO-donating pro-drugs on B-CLL cells in vitro. We demonstrate that combinations of fludarabine with the NO donor, DETA-NO exhibit synergistic cytotoxicity for B-CLL lymphocytes in a leukemia and drug-selective manner. Moreover, B-CLL cells that exhibit emerging resistance to fludarabine alone remain sensitive to the combination of fludarabine with DETA-NO.
Materials and methods

Chemotherapeutic agents
The chemotherapeutic agents used in this study were obtained from the following sources: fludarabine, Berlex Laboratories, Richmond, CA, USA; doxorubicin and 5-fluorouracil, Pharmacia, Kalamazoo, MI, USA; gemcitabine, Lilly, Indianapolis, IN, USA; SN-38, Research Triangle Institute, Research Triangle Park, NC, USA. Nelarabine (506U78; 2-amino-9-␤-d-6-methoxy ara-guanine) was a gift from Dr Joanne Kurtzberg, Department of Pediatrics, Duke University Medical Center, Durham, NC, USA. The diazenium diolate NO pro-drugs were purchased from Cayman Chemical, Ann Arbor, MI, USA. Interleukin-4 (IL-4) and diethylene triamine (DETA) were purchased from Sigma Chemical, St Louis, MO, USA.
Isolation of B-CLL lymphocytes
B-CLL patients from the Veteran's Affairs (VA) Medical Center and Duke University Medical Center were enrolled in this study under a protocol approved by the Duke University and VA Institutional Review Boards. Blood was collected into heparinized Vacutainer CPT mononuclear cell preparation tubes (Becton-Dickinson Vacutainer Systems, Franklin Lakes, NJ, USA), and centrifuged at 1500 g for 15 min at room temperature. The mononuclear cell layer was harvested, washed, and cultured overnight in RPMI 1640 growth medium (Gibco, Grand Island, NY, USA), supplemented with 10% heat-inactivated fetal bovine serum (HyClone, Logan, UT, USA), 1% penicillin-streptomycin-amphotericin B (Sigma Chemical), and IL-4 (5 ng/ml) in culture flasks to remove monocytes/macrophages. After overnight culture, T cells were removed with magnetic immunobeads (Dynabeads, Dynal, Princeton, NJ, USA) for samples with white blood cell counts less than 50 000/l. Residual red blood cells were then removed by centrifugation over Ficoll-Paque Plus (Pharmacia, Uppsala, Sweden).
Metabolic inhibition assay
The MTS cell proliferation assay (Celltiter 96 AQ, Promega, Madison, WI, USA) was used to assess drug effects on cell viability. Cells were plated at 2.5 × 10 5 cells/well in 96-well microtiter plates (Corning Costar, Acton, VT, USA). Triplicate wells were exposed to varying concentrations of agents for 72 h at 37°C. MTS reagent (20 l) was then added to each well for the final 3 h of culture, and the absorbance at 490 nm (A 490 ) was quantitated in an absorbance plate reader (Bio-Tek, Winooski, VT, USA). Response was defined as (mean drugtreated A 490 − blank)/(mean untreated control A 490 − blank) × 100. The data were curve fit by weighted non-linear regression to determine the IC 50 , defined as the drug concentration that inhibited MTS metabolism to 50% of untreated controls.
Assessment of drug interaction
Drug interaction was assessed by a modification of the combination index method of Chou and Talalay. 14 Agents were combined in a ratio equal to the ratio of their individual IC 50 s and evaluated in the MTS assay. The combination index, CI, was assessed at the IC 50 level of effect and defined as: An additive interaction is then defined as Cl = 1, antagonism as CI Ͼ 1, and synergy as CI Ͻ 1. Since the mean 95% confidence interval for all interactions was 0.135, a CI Ͻ 0.6 was used to define a statistically significant level of synergy. An extension of the Chou and Talalay approach was also used to assess drug interaction. The three-dimentional model of Kanzawa et al 15 computes a combination effect (CE) surface that identifies the range of each drug concentration that yields either additive (CE = 0), greater than additive (CE Ͼ 0), or less than additive (CE Ͻ 0) interactions. This model provides a global view of drug interaction that incorporates multiple drug ratios and levels of effect in a single graphic, which in this study is a color-coded contour map. The contour map represents the combination effect surface that is generated by subtracting a surface of theoretical additivity (TA), from an observed response surface. Theoretical additivity is defined by the equation TA = (f a ) A + (f a ) B − (f a ) A (f a ) B , where (f a ) A and (f a ) B are the fractions of cells affected by drugs A and B, respectively, and where the two drugs have mechanisms of action that are not independent. In practice, data in an 8 × 8 well matrix format from six replicate plates were entered into a Microsoft Excel (Redmond, WA, USA) spreadsheet where the combination effect surface was computed and the result converted to XYZ format. Contour plots were then produced using SigmaPlot 2000 (SPSS, Chicago, IL, USA) scientific graphics software. A contour plot of the respective fractions affected for the combination was also constructed to correlate drug interaction with efficacy.
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Annexin V apoptosis assay
The annexinV/propidium iodide assay (R&D Systems, Minneapolis, MN, USA) was used according to the manufacturer's protocol to assess drug effects on B-CLL cell apoptosis. Briefly, B-CLL cells (5 × 10 6 in 4 ml) were cultured in six-well cluster dishes in the presence or absence of study agents for various times. Cells were then washed and resuspended in Dulbecco's phosphate-buffered saline, incubated with the respective fluorescent probes and analyzed by flow cytometry at 530 nm (annexin V FITC) and 585 nm (PI) on a FACScan flow cytometer with Cell Quest software (Becton Dickinsen). Results were expressed as the percentage of cells that were viable (AV−/PI−), apoptotic (AV+/PI−), or dead (AV+/PI+).
Inhibition of RNA synthesis
Drug effects on RNA synthesis were evaluated by measurement of cellular incorporation of [ 
Results
Cytotoxicity of fludarabine and nitric oxide against cultured B-CLL lymphocytes
We sought to identify drug combinations containing fludarabine that exhibit synergistic cytotoxicity toward B-CLL lymphocytes. In particular, we wished to examine combinations with NO-donating agents and other agents known to affect nucleic acid metabolism. To this end, peripheral blood lymphocytes were isolated from whole blood donated by 28 consenting B-CLL patients (median age 63, range 43-84 years). Twenty-one of 28 (75%) were male, and 9/28 (31%) were previously untreated. Pilot studies aimed at optimizing culture conditions revealed a significant amount of spontaneous apoptosis after 72 h incubation in RPMI growth medium. Since this effect could cloud interpretation of chemosensitivity assays, we examined various medium supplements to improve viability. We found that addition of interleukin 4 was sufficient to maintain B-CLL viability over the required assay period and did not significantly affect drug interactions described below (data not shown). The cytotoxicity of fludarabine was then compared to that of other DNA anti-metabolites, the topoisomerase I inhibitor SN-38 (the active metabolite of the clinical agent, irinotecan), the topoisomerase II inhibitor doxorubicin, and the alkylating agent chlorambucil. Following drug exposure for 3 days, the viability of B-CLL cells was determined with the MTS assay. The results are summarized in Table 1 . The IC 50 of fludarabine was nearly a log greater than either SN-38 or doxorubicin, but was seven to 400 times less than other DNA anti-metabolities, and chlorambucil, which is the traditional first-line therapy in B-CLL.
Based on observations that NO induces apoptosis and death of acute nonlymphocytic leukemia (ANLL) cells in vitro, 13 we evaluated the ability of exogenous NO to kill B-CLL cells. Specifically, we examined 1-substituted diazen-1-ium-1,2-diolates as NO donors in which NO is released at known rates in vitro. 17 The NO prodrugs were cytotoxic for B-CLL cells at relatively low concentrations. For example, the compound
, which releases half its NO in 20 h at 37°C, had an average IC 50 of approximately 300 m in B-CLL specimens (Table 1 ). This represents an exposure rate of 0.25 m NO/min, which is well within the steady state concentration noted in vivo (0.01-1 m). [18] [19] [20] Moreover, DETA-NO achieved a higher level of cell kill than typically observed with chemotherapeutic agents in this assay. Cytotoxicity was due specifically to released NO, because DETA alone and DETA-NO that had been extensively pre-incubated prior to treatment were both inactive in six separate specimens (data not shown).
To determine whether NO toxicity was a function of NO release rate, we evaluated the diazenium diolate analogues, MAHMA-NO and PAPA-NO, which have release half times of 1 and 15 min, respectively. The results shown in Figure 1a indicate that there is an inverse log relationship between NO release rate and in vitro cytotoxicity. Thus, exposure time is a critical factor in nitric oxide-mediated toxicity toward B-CLL cells. These results are consistent with those reported by Shami et al, 13 who found a similar correlation of release rate to cytotoxicity for these NO donors when assayed against HL60 and U937 cell lines, representing acute myeloblastic and acute monoblastic lineages, respectively.
Interactions of fludarabine and nitric oxide
Next, we evaluated binary combinations of fludarabine using the combination index method of Chou and Talalay. 14 Agents were evaluated by simultaneous exposure and combined at the ratio of their IC 50 s to minimize the number of leukemia cells required and to facilitate data analysis. Similarly, the combination index endpoint was also defined at the IC 50 which may not reflect optimal drug interaction conditions (see Table 1 Chemosensitivity Figure 2 . The median effect plots for each agent alone and in combination are given in panel(a). Because none of these lines is parallel, exclusivity of the interaction cannot be determined.
14 The resulting combination index plot in panel (b) describes an interaction that can be antagonistic, additive or synergistic depending on the drug concentrations and related level of effect. At the IC 50 (fraction affected = 0.5), the interaction is moderately synergistic (ie combination index = 0.64), while at higher levels of effect, the interaction becomes increasingly more synergistic.
The sequence of agent exposure can also be an important parameter in drug interactions. In B-CLL cell specimens from three patients, sequential exposure to fludarabine and DETA-NO in either sequence after a 24 h interval produced a similar interaction when compared to simultaneous administration (data not shown). This result suggests that the effect of NO was not due to increased dephosphorylation of fludarabine to its nucleoside form (F-ara-A) prior to drug uptake by cells. Accordingly, when the activity of fludarabine was compared directly to that of F-ara-A in 10 B-CLL patient samples, the results were equivalent (mean IC 50 = 1.74 vs 1.68, respectively). In addition, the interaction of F-ara-A with The combination index (circles) was computed at increasing levels of effect for the specimen above where CI Ͻ1 indicates synergy; CI = 1, additivity; CI Ͼ1, antagonism.
DETA-NO was similar (mean ratio of combination indices at the IC 50 for (F + DETA-NO)/(F-ara-A + DETA-NO) = 0.89 ± 0.13). Of note, there was no significant effect of NO release time on the interaction of fludarabine and NO on B-CLL samples (Figure 1b) .
A different perspective on the interaction of fludarabine and DETA-NO is shown in Figure 3 , where the combination index (CI) is plotted as a function of sensitivity to fludarabine. The data exhibit a hyperbolic relationship that can be fit by the equation:
CI at IC 50 FLU+DETA-NO = 0.88 (IC 50 FLU ) 0.36 .
This result suggests that NO may preferentially sensitize leukemia cells to fludarabine that otherwise express emerging resistance to fludarabine alone.
Specificity of the fludarabine-NO interaction
To determine whether the synergistic interaction between fludarabine and NO was drug-specific, we evaluated combinations of DETA-NO with other DNA antimetabolites, with
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Figure 3
Interaction of fludarabine and DETA-NO as a function of fludarabine sensitivity. Combination indices from 56 patient samples (circles) were plotted as a function of the sensitivity to fludarabine phosphate alone. The data was then fit to the hyperbolic function y = a/(x) n , where a = 0.88, n = 0.36. Dotted lines, 95% confidence intervals.
topoisomerase I and II inhibitors, and with chlorambucil, the traditional first-line agent in B-CLL. The results summarized in panel (a) of Figure 4 reveal a notable selectivity for the interaction of fludarabine and DETA-NO. While synergy was not specific for fludarabine, the ara-G prodrug nelarabine was the only DNA antimetabolite to exhibit a comparable interaction. Almost 90% of the specimens treated with nelarabine + DETA-NO had a combination index Ͻ0.6, compared to 52% of samples exposed to fludarabine + DETA-NO. In contrast, interactions with the other agents tested were additive and not synergistic.
To judge the relative potency of the fludarabine-DETA-NO combination, we examined other drug combinations in this series by the same method. Figure 4b demonstrates that the degree of interaction between fludarabine and DETA-NO is similar to that observed for the combination of fludarabine with the topoisomerase II inhibitor doxorubicin (51% samples with CI Ͻ0.6). Likewise, combination of fludarabine with the topoisomerase I inhibitor SN-38 (the active metabolite of CPT-11) produced this level of synergy in 42% of specimens, while combinations of SN-38 with chlorambucil or doxorubicin were less effective (22% and 12% specimens with CI Ͻ0.6, respectively).
Three-dimensional analysis of the fludarabine interaction with DETA-NO
To obtain a more global perspective on the interaction of fludarabine with DETA-NO, we applied the three-dimensional modeling approach of Kanzawa et al 15 to four separate specimens from a representative patient. The resulting combination effect (CE) surface (shown as a contour plot in Figure 5a DETA-NO rapidly converted to additivity, and then to a region of antagonism (red area). While interpretation is clearly limited to analyses of multiple samples from a single individual, this result indicates that evaluation of combinations at a single drug ratio (such as the IC 50 of each agent) may not reveal optimal interaction, and that concentrations of fludarabine and DETA-NO must be carefully controlled to maximize a synergistic anti-leukemia effect.
Effect of fludarabine and DETA-NO on B-CLL apoptosis
Both fludarabine and NO are known to cause cell death via apoptosis, which is a primary pathway for cell death induced by cytotoxic agents in hematological malignancies. 21, 22 Because the observation of a synergistic interaction between fludarabine and DETA-NO was made using a metabolic assay, which can underestimate the number of apoptotic cells (data not shown), we performed B-CLL cell annexin-V apoptosis assays. Figure 6 summarizes results from five patient specimens. The time course reveals that there is a significant two-
Figure 5
Three-dimensional combination effect surface for the interaction of fludarabine and DETA-NO in B-CLL lymphocytes. The three-dimensional method of Kanzawa et al 15, 48 was used to obtain a global view of the interaction of fludarabine phosphate and DETA-NO in a representative patient. (a) The mean combination effect surface from four separate determinations reveals a continuum of response from highly antagonistic (light) to highly synergistic (dark). Superimposed white contour lines indicate regions of synergy (Ͼ1) or antagonism (Ͻ−1) that are significant at the 95% confidence level. The white star indicates the interaction at drug concentrations that produce an IC 50 level of effect for each agent alone (standard twodimensional format). (b) Corresponding efficacy plot for (a) showing the percent of B-CLL lymphocytes affected (F a ), ranging from minimal (dark) to maximal (light). Optimum synergy corresponds to a region of 80-90% cell kill.
fold increase in apoptosis with the combination of fludarabine and DETA-NO at 24 h, and that this effect is eventually translated into an increase in dead cells at 48 and 72 h compared to either agent alone. In contrast, there was no significant loss of viability in untreated B-CLL cells over this time frame.
Mechanisms underlying the effects of fludarabine and DETA-NO in B-CLL
A recent report demonstrates that the mechanism of fludarabine action in B-CLL involves inhibition of RNA synthesis as reflected by cellular [ 3 H]uridine incorporation. 23 Consequently, we determined whether there was a correlation between cytotoxicity measured by inhibition of MTS metabolism and cytotoxicity measured by inhibition of [ 3 H]uridine incorporation in B-CLL cells treated with fludarabine in the presence and absence of DETA-NO. In assays on three separate specimens, there was a high correlation between these two endpoints of cytotoxicity (Table 2) . When the combination index for drug interaction assessed by mitochondrial metabolism (MTS assay) was compared to that evaluated by RNA synthesis (uridine incorporation), the correlation was weaker, yet still statistically significant. This suggests that inhibition of RNA synthesis contributes to, but may not be the sole mechanism of interaction between fludarabine and NO.
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Discussion
Fludarabine is very active as salvage therapy for B-CLL, and some now consider it first-line therapy for B-CLL. The drug also has activity in other indolent lymphoid malignancies. Paradoxically, fludarabine (unlike the pyrimidine nucleoside analog gemcitabine) does not have comparable activity against solid tumors.
24 Fludarabine is also an important partner for combination chemotherapy. Consistent with our results, Kano and colleagues 25 found additive effects of fludarabine with doxorubicin in a B-CLL cell line. Additive effects were also seen with etoposide, 4-hydroperoxy-cyclophosphamide and hydroxyurea, while synergy was observed with cytarabine in vitro. Accordingly, fludarabine has demonstrated clinical activity in combination chemotherapy regimens with cyclophosphamide, mitoxantrone, mitoxantrone + dexamethasone/prednisone, and idarubicin. 24, 26 Inhibition of DNA replication via incorporation of F-ara-ATP and subsequent chain termination is thought to be the primary mechanism of fludarabine action in replicating cells. 27 Several related molecular targets have been identified. These include ribonucleotide reductase, DNA polymerases ␣, ␤, ␥, and ⑀, DNA primase, and DNA ligase. 27 Fludarabine inhibits DNA elongation, and once it is incorporated into nucleic acid, it is a poor substrate for DNA excision repair. In addition, fludarabine directly inhibits DNA repair enzymes. 28 The effects of fludarabine on DNA replication are not likely the mechanism of cytotoxicity in these non-cycling cells. Four other actions of fludarabine have been reported that could account for anti-leukemia activity in B-CLL lymphocytes. (1) F-ara-ATP is incorporated into DNA of quiescent cells by repair synthesis. 29 The resulting chain termination and free DNA ends may trigger apoptosis. (2) Unlike ara-C and ara-A, fludarabine inhibits RNA synthesis due to preferential incorporation of F-ara-A into messenger RNA with resulting premature termination of the transcript. 30 Other DNA-directed drugs have also been found to target RNA in B-CLL. For example, Cohen et al 16 reported a strong correlation between cytotoxicity and inhibition of RNA synthesis in B-CLL patient samples treated in vitro with the topoisomerase I inhibitor SN-38. Results reported here are consistent with this mechanism of cytotoxicity. While general inhibition of RNA synthesis is an important mechanism, loss of specific transcripts might also be critical. Huang and colleagues 23 observed loss of a 50 kDa protein in B-CLL cells after fludarabine treatment. (3) Another mechanism for fludarabine cytotoxicity that is independent of either DNA or RNA synthesis has been reported: direct activation of apoptosis. In a reconstituted, cell-free system, highly purified cytochrome-c was incubated with recombinant apoptosis protein activating factor 1 (Apaf-1) and recombinant procaspase-3 and -9. 31 Addition of F-ara-ATP had a catalytic efficiency almost 50 times that of the natural substrate, deoxy-ATP for causing cleavage of these pro-caspases to their active forms, which subsequently initiate apoptosis. (4) Finally, Frank et al 32 have shown that fludarabine specifically depletes normal resting or activated human lymphocytes of the protein and mRNA for STAT1, which is constitutively phosphorylated in B-CLL cells and may promote B-CLL cell viability. 33 NO is also an important regulator of apoptosis in B-CLL lymphocytes. NO appears to be a double-edged sword depending on the redox state of the cell and whether cell exposure is endogenous or exogenous. 8, 9, 34, 35 For example, in B-CLL lymphocytes, NOS2 can be increased 10-to 15-fold, 34 leading to elevated endogenous NO that exerts an anti-apoptotic effect. 9 With brief exposures, exogenous NO can delay apoptosis in cultured, mature murine B cells, an effect that is correlated to stabilization of both the mRNA and protein levels of the anti-apoptotic factor, bcl-2. 8 Endogenous NO can inhibit Fas-induced apoptosis in human B cell, T cell and monocytic cell lines 36 probably via S-nitrosylation of the active site thiols of cysteine proteases, including the caspase family. Finally, NOS2 inhibitors can induce apoptosis in B-CLL cells. 9, 34 On the other hand, high level NO production is an important component of host immune defense against neoplasia, since NO is a prominent mediator of macrophagemediated tumor cell cytotoxicity. 37 Potential mechanisms of toxicity include N-nitrosation of DNA and covalent modification of tyrosine residues, 38 inhibition of mitochondrial respiration and inhibition of the glycolytic enzymes aconitase 39, 40 and glyceraldehyde-3-phosphate dehydrogenase. 41, 42 Moreover, metal-and thiol-containing proteins are also major NO targets, and include DNA ligase 43 and ribonucleotide reductase, 38 which are also fludarabine targets and could account for the observed synergy between NO donors and fludarabine in B-CLL lymphocytes. Therefore, whether NO is an agent of life or death for cells appears to depend on the source, concentration and flux of NO, the type of cell and its redox state and the presence of competing NO scavengers and NOS inhibitors.
Despite the multiple cellular pathways regulated by nitric oxide, surprisingly little is known about the interaction of this potent molecule with anti-cancer chemotherapeutic agents. Wink and colleagues evaluated combinations of NO donors with the alkylating agents BCNU, 28 cisplatin, 44 and melphalan 45 by clonogenic assay in replicating V79 Chinese hamster lung fibroblasts and MCF-7 human breast cancer cells. In each case, NO released by the diazenium diolate donor, DEA/NO significantly enhanced cytotoxicity of the alkylating agent, possibly by inhibition of DNA repair. However, DEA/NO had cytotoxic activity alone, and an interaction endpoint analysis (eg the combination index we used here) was not determined. Hence, direct comparison of the results of Wink et al with our results is not possible. In the case of quiescent B-CLL lymphocytes, we did not observe enhanced activity of the alkylating agent chlorambucil with NO. Rather, we found that the interaction of DETA-NO at its IC 50 for B-CLL cells with the agents tested was highly selective for the DNA anti-metabolites, and that there were differences within this class of chemotherapeutic agent. The molecular basis for this selectivity is unknown, but it suggests the interaction of these agents could be clinically important. Indeed, in preliminary studies, the combination of fludarabine with DETA-NO produced synergistic activity in cell culture models of human breast cancer, whereas fludarabine alone was virtually inactive at equivalent concentrations. Ultimately, the utility of combinations of DNA anti-metabolites with NO donors will depend on the specificity of the interaction for leukemia cells. Our preliminary data with normal peripheral blood mononuclear cells suggests that a therapeutic window of specificity could exist. In four of five normal blood mononuclear cell samples, the interaction of fludarabine with DETA-NO was additive (CI = 1.0 ± 0.1), rather than synergistic. These samples contain only a small percentage of normal B cells, and therefore do not represent a true normal control for B-CLL. However, if NO-fludarabine combinations prove to be selectively cytotoxic for leukemia cells, such a combination would be very useful clinically. With advances in development of NO pro-drugs such as those targeted to specific tissues and cell types, 46 ,47 a very high therapeutic ratio might be achieved. Finally, combination of fludarabine and nitric oxide could enhance drug activity in solid tumors, as well as in fludarabine-resistant leukemias.
